搜索头条

“Lilly”

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Business News · 2026年9月25日 12:51

商业与经济

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

Business News · 2026年9月21日 19:37

商业与经济

Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space.

Business News · 2026年9月21日 18:57